Amgen receives NMPA approval for Repatha® (evolocumab) In China to reduce the risk of cardiovascular events

Alternative Medicine
AmgenAmgen (NASDAQ:AMGN) announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha® (evolocumab) as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization.

Leave a Reply

Your email address will not be published. Required fields are marked *